Sukhi Jagpal
CIK 1554591 · Chief Financial Officer · last filed 2026-06-09
Sukhi Jagpal is a Chief Financial Officer who has filed 19 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for STRO, was dated Jun 9, 2026. Across all open-market trades the lifetime net is −$628.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $35.5K across reported positions. 4 SEC filings were submitted jointly with QLT INC/BC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
QLTI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1820 GATEWAY DRIVE, SUITE 110
SAN MATEO, CA 94404
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STRO | Director | — | $10.94 | — | $0 | 4 | 2026-06-09 |
| Sierra Oncology, Inc. (SRRA) Delisted | Chief Financial Officer | — | $54.99 | — | $0 | 10 | 2022-07-01 |
| Sierra Oncology, Inc. (DNAI) Delisted | Chief Financial Officer | — | — | — | $0 | 2 | 2016-10-04 |
| QLTI | Chief Financial Officer | 1,300 | $27.33 | $35.5K | -$628.2K | 3 | 2013-07-17 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-09 | STRO | Grant (A) | — | $0 | EDGAR |
| 2025-12-29 | STRO | Grant (A) | — | $0 | EDGAR |
| 2025-06-10 | STRO | Grant (A) | — | $0 | EDGAR |
| 2024-08-12 | STRO | Grant (A) | — | $0 | EDGAR |
| 2022-07-01 | Sierra Oncology, Inc. (SRRA) Delisted | Disp (D) | — | $0 | EDGAR |
| 2022-06-17 | Sierra Oncology, Inc. (SRRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-14 | Sierra Oncology, Inc. (SRRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-28 | Sierra Oncology, Inc. (SRRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-17 | Sierra Oncology, Inc. (SRRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-12 | Sierra Oncology, Inc. (SRRA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.